|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
|
27696107 |
2017 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
CausalMutation
|
disease |
CLINVAR |
Functional analysis of a novel missense mutation in AXIN2 associated with non-syndromic tooth agenesis.
|
27090353 |
2016 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Expression and localization of axin 2 in colorectal carcinoma and its clinical implication.
|
23702820 |
2013 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity.
|
22745173 |
2012 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
CausalMutation
|
disease |
CLINVAR |
Mutations in WNT10A are present in more than half of isolated hypodontia cases.
|
22581971 |
2012 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
GermlineCausalMutation
|
disease |
ORPHANET |
AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.
|
21416598 |
2011 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
GeneticVariation
|
disease |
CLINVAR |
AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.
|
21416598 |
2011 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.
|
21416598 |
2011 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability.
|
16247484 |
2006 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
GeneticVariation
|
disease |
BEFREE |
Recently, germline mutations in the Wnt pathway component gene AXIN2 have been associated with tooth agenesis-colorectal cancer syndrome.
|
16941501 |
2006 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer.
|
16815967 |
2006 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CLINGEN |
Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.
|
15042511 |
2004 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
GeneticVariation
|
disease |
CLINVAR |
Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.
|
15042511 |
2004 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.
|
15042511 |
2004 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
CausalMutation
|
disease |
CLINVAR |
Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.
|
15042511 |
2004 |
|
Oligodontia-Colorectal Cancer Syndrome
|
0.710 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate β-catenin and AXIN2 expression in colorectal cancer (CRC) and relate these findings with patients' clinicopathological features and prognosis.
|
28534366 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Finally, we determined that miR-30-5p attenuates the expression of Wnt/β-catenin signaling target genes (Axin2 and MYC), Wnt luciferase activity, and β-catenin protein levels in CRC stem cells.
|
30338942 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Together, our study identifies a novel function of miR-103/107 in promoting colorectal cancer stemness by targeting Axin2 and elucidates the clinical relevance and prognostic value of this axis in colorectal cancer.
|
31273221 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aims to determine the contribution of polymorphisms in the genes of the β-catenin destruction complex to develop CRC, specifically adenomatous polyposis coli (APC) (rs11954856 G>T and rs459552 A>T), axis inhibition protein 1 (AXIN1) (rs9921222 C>T and rs1805105 C>T), AXIN2 (rs7224837 A>G), and dishevelled 2 (DVL2) (2074222 G>A and rs222836 C>T).
|
31723073 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied thirteen single nucleotide polymorphisms (SNPs) located in SFRP3 (rs7775), CTNNB1 (β-catenin) [rs4135385, rs13072632], APC (rs454886, rs459552), LRP6 (rs2075241, rs2284396), DKK4 (rs3763511), DKK3 (rs6485350), TCF4 (rs12255372) and AXIN2 (rs3923086, rs3923087, rs4791171) in patients with colorectal cancer (n = 122) and controls (n = 110).
|
31485167 |
2019 |
|
Hypodontia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Study of rs12532, rs8670 Polymorphism of Msh Homeobox 1 (MSX1), rs61754301, rs4904155 Polymorphism of Paired Box Gene 9 (PAX9), and rs2240308 Polymorphism of Axis Inhibitor Protein 2 (AXIN2) Genes in Nonsyndromic Hypodontia.
|
31781599 |
2019 |
|
Hypodontia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this case report we describe a family with c.1972delA, p.Ser658Alafs*31 nonsense variant in AXIN2 where the three confirmed carriers presented with both oligodontia and colorectal adenomatous polyposis; mean number of teeth missing in carriers was 16.5 (range 11-22) and mean number of polyps in carriers was 49 (range 5->100, polyps were predominantly adenomatous).
|
30671715 |
2019 |
|
Oligodontia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this case report we describe a family with c.1972delA, p.Ser658Alafs*31 nonsense variant in AXIN2 where the three confirmed carriers presented with both oligodontia and colorectal adenomatous polyposis; mean number of teeth missing in carriers was 16.5 (range 11-22) and mean number of polyps in carriers was 49 (range 5->100, polyps were predominantly adenomatous).
|
30671715 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, Axin2 may serve as either a promoter or suppressor of tumors, and the effects of its inhibition on the cell proliferation and metastasis of CRC require further elucidation.
|
29534875 |
2018 |